Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.81 |
| ▸ | NQO2 | P16083 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.49 |
| ▸ | FYN | P06241 | 4/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2697147 | 0.90 | MET (1.00) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL12048995 | 0.83 | MET (0.79) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL3435424 | 0.77 | MET (0.78) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1658513 | 0.77 | MET (0.78) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL10242215 | 0.75 | MET (0.72) | METPDE3BPDE3A | |
| SCHEMBL2697192 | 0.75 | MET (1.00) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL10242437 | 0.75 | MET (0.55) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL2697690 | 0.74 | MET (0.55) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1656793 | 0.74 | MET (0.74) | MET | |
| SCHEMBL1656820 | 0.73 | MET (0.69) | METNQO2PDE3BPDE3APIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885NQO2 1016/4885PDE3B 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.